Skip to main content

Advertisement

SpringerLink
Log in

The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs.

Methods

Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension—five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query

Results

A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from − 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61–0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities.

Conclusions

Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets generated and analysed during the current study are available from the corresponding author upon reasonable request.

References

  1. Richeldi, L., Collard, H. R., & Jones, M. G. (2017). Idiopathic pulmonary fibrosis. The Lancet, 389(10082), 1941–1952. https://doi.org/10.1016/s0140-6736(17)30866-8.

    Article  Google Scholar 

  2. Swigris, J. J., & Fairclough, D. (2012). Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest, 142(2), 291–297. https://doi.org/10.1378/chest.11-2602.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cox, I. A., Arriagada, N. B., de Graaff, B., Corte, T. J., Glaspole, I., Lartey, S., Walters, E. H., & Palmer, A. J. (2020). Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. European Respiratory Review, 29(158), 200154. https://doi.org/10.1183/16000617.0154-2020.

    Article  PubMed  Google Scholar 

  4. York Health Economics Consortium (2016). Preference based measures. hhttps://yhec.co.uk/glossary/preference-based-measures/. Accessed 5 Oct 2020.

  5. Drug Utilisation Sub-committee PBAC (2020). Nintedanib and pirfenidone: 24 month predicted versus actual analysis. Canberra, Australia: Pharmaceutical Benefits Scheme, Commonwealth Department of Health, Government of Australia. https://www.pbs.gov.au/pbs/industry/listing/participants/public-release-docs/2020-02/nintedanib-and-pirfenidone-24-month-predicted-versusactual. Accessed 10 July 2020.

  6. EuroQol Research Foundation (2020). EQ-5D-5L about. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/. Accessed 20 Jun 2020.

  7. Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European Journal of Health Economics, 21(8), 1245–1257. https://doi.org/10.1007/s10198-020-01195-8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., & Allan, H. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 02. https://doi.org/10.1183/13993003.01592-2016.

    Article  Google Scholar 

  9. Moodley, Y., Goh, N., Glaspole, I., Macansh, S., Walters, E. H., Chapman, S., et al. (2014). Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project. Respirology, 19(7), 1088–1091. https://doi.org/10.1111/resp.12358.

    Article  PubMed  Google Scholar 

  10. Kolb, M., & Collard, H. R. (2014). Staging of idiopathic pulmonary fibrosis: Past, present and future. European Respiratory Reviews, 23(132), 220–224. https://doi.org/10.1183/09059180.00002114.

    Article  Google Scholar 

  11. Puxeddu, E., & Rogliani, P. (2016). Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis. World Journal of Respirology. https://doi.org/10.5320/wjr.v6.i1.14.

    Article  Google Scholar 

  12. Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., & King, T. E., Jr. (2012). A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine, 156(10), 684–695. https://doi.org/10.7326/0003-4819-156-10-201205150-00004.

    Article  PubMed  Google Scholar 

  13. Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., & Reynolds, P. (2018). Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: Analysis from the Australian IPF registry. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-018-0575-y.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S., Cramer, D., Nicholson, A. G., Colby, T. V., Du Bois, R. M., & Hansell, D. M. (2013). Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. American Journal of Respiratory and Critical Care Medicine, 167(7), 962–969. https://doi.org/10.1164/rccm.2111053.

    Article  Google Scholar 

  15. Erbes, R., Schaberg, T., & Loddenkemper, R. (1997). Lung function tests in patients with idiopathic pulmonary fibrosis: Are they helpful for predicting outcome? Chest, 111(1), 51–57. https://doi.org/10.1378/chest.111.1.51.

    Article  CAS  PubMed  Google Scholar 

  16. Lopes, A. J., Capone, D., Mogami, R., Lanzillotti, R. S., Melo, PLd., & Jansen, J. M. (2011). Severity classification for idiopathic pulmonary fibrosis by using fuzzy logic. Clinics, 66(6), 1015–1019. https://doi.org/10.1590/s1807-59322011000600016.

    Article  PubMed  PubMed Central  Google Scholar 

  17. EuroQol Research Foundation (2020). EQ-5D-3L about. hhttps://euroqol.org/eq-5d-instruments/eq-5d-3l-about/. Accessed 15 Nov 2020.

  18. R Core Team. (2019). R: A language and environment for statistical computing. (3.5.1). Vienna: R Foundation for Statistical Computing.

    Google Scholar 

  19. Morton, F., & Nijjar, J. S. (2019). “eq5d” package: Methods for Analysing ‘EQ-5D’ Data and Calculating ‘EQ-5D’ Index Scores. https://cran.r-project.org/web/packages/eq5d/index.html. Accessed June 20 2020.

  20. StataCorp. (2019). Stata statistical software: Release 16. Texas: StataCorp LLC.

    Google Scholar 

  21. EuroQol Research Foundation (2020). EQ-5D-5L valuation: Standard value sets. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standardvalue-sets/. Accessed 5 Oct 2020.

  22. Norman, R., Cronin, P., & Viney, R. (2013). A pilot discrete choice experiment to explore preferences for EQ-5D-5L Health states. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-013-0035-z.

    Article  PubMed  Google Scholar 

  23. Van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., Lloyd, A., Scalone, L., Kind, P., & Pickard, A. S. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 15(5), 708–715. https://doi.org/10.1016/j.jval.2012.02.008.

    Article  PubMed  Google Scholar 

  24. EuroQol Research Foundation (2019). EQ-5D-5L Valuation Crosswalk Index Value Calculator. https://euroqol.org/eq-5d-instruments/eq-5d-5labout/valuation-standard-value-sets/crosswalk-index-value-calculator/. Accessed 5 Oct 2020.

  25. EuroQol Research Foundation (2019). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/. Accessed 5 Oct 2020.

  26. Jo, H. E., Troy, L. K., Keir, G., Chambers, D. C., Holland, A., Goh, N., Wilsher, M., De Boer, S., Moodley, Y., Grainge, C., & Whitford, H. (2017). Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 22(7), 1436–1458. https://doi.org/10.1111/resp.13146.

    Article  PubMed  Google Scholar 

  27. Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., & Johkoh, T. (2015). An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 192(2), e3–e19. https://doi.org/10.1164/rccm.201506-1063ST.

    Article  PubMed  Google Scholar 

  28. Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., & Flaherty, K. R. (2018). Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 198(5), e44–e68. https://doi.org/10.1164/rccm.201807-1255ST.

    Article  PubMed  Google Scholar 

  29. Akgun, K. M., Crothers, K., & Pisani, M. (2012). Epidemiology and management of common pulmonary diseases in older persons. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences., 67(3), 276–91. https://doi.org/10.1093/gerona/glr251.

    Article  Google Scholar 

  30. Nolan, C. M., Longworth, L., Lord, J., Canavan, J. L., Jones, S. E., Kon, S. S., & Man, W. D. (2016). The EQ-5D-5L health status questionnaire in COPD: Validity, responsiveness and minimum important difference. Thorax, 71(6), 493. https://doi.org/10.1136/thoraxjnl-2015-207782.

    Article  PubMed  Google Scholar 

  31. Dowman, L. M., McDonald, C. F., Hill, C. J., Lee, A. L., Barker, K., Boote, C., Glaspole, I., Goh, N. S. L., Southcott, A. M., Burge, A. T., Gillies, R., Martin, A., & Holland, A. E. (2017). The evidence of benefits of exercise training in interstitial lung disease: A randomised controlled trial. Thorax, 72(7), 610–619. https://doi.org/10.1136/thoraxjnl-2016-208638.

    Article  PubMed  Google Scholar 

  32. Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950–956. https://doi.org/10.1111/resp.12989.

    Article  PubMed  Google Scholar 

  33. Corte, T., Bonella, F., Crestani, B., Demedts, M. G., Richeldi, L., Coeck, C., Pelling, K., Quaresma, M., & Lasky, J. A. (2015). Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 16, 116–116. https://doi.org/10.1186/s12931-015-0276-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. King, T. E., Jr., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stahler, G., Leconte, I., Roux, S., & Raghu, G. (2008). BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 177(1), 75–81.

    Article  CAS  Google Scholar 

  35. King, T. E., Jr., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., & Behr, J. (2011). BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 184(1), 92–99. https://doi.org/10.1164/rccm.201011-1874OC.

    Article  Google Scholar 

  36. Kolb, M., Raghu, G., Wells, A. U., Behr, J., Richeldi, L., Schinzel, B., Quaresma, M., Stowasser, S., & Martinez, F. J. (2018). Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1811737.

    Article  Google Scholar 

  37. Wailoo, A. J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., Botteman, M., & Busschbach, J. (2017). Mapping to estimate health-state utility from non–preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20(1), 18–27. https://doi.org/10.1016/j.jval.2016.11.006.

    Article  PubMed  Google Scholar 

  38. Caminati, A., Cassandro, R., Torre, O., & Harari, S. (2017). Severe idiopathic pulmonary fibrosis: What can be done? European Respiratory Review. https://doi.org/10.1183/16000617.0047-2017.

    Article  PubMed  Google Scholar 

  39. Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., Hagmeyer, L., Skowasch, D., Meyer, J. F., Kirschner, J., Gläser, S., Herth, F. J. F., Welte, T.,…Behr, J. (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respiratory Research, 18(1), 139. https://doi.org/10.1186/s12931-017-0621-y.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Szentes, B. L., Kreuter, M., Bahmer, T., Birring, S. S., Claussen, M., Waelscher, J., Leidl, R., & Schwarzkopf, L. (2018). Quality of life assessment in interstitial lung diseases: A comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respiratory Research. https://doi.org/10.1186/s12931-018-0808-x.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Case, A. H., Hellkamp, A. S., Neely, M. L., Bender, S., Dilling, D. F., Gulati, M., Hotchkin, D. L., Huie, T. J., Lancaster, L., Snyder, L. D., Conoscenti, C. S., & Palmer, S. M. (2020). Associations between patient-reported outcomes and death or lung transplant in IPF: Data from the IPF-PRO registry. Annals of the American Thoracic Society. https://doi.org/10.1513/AnnalsATS.201906-437OC.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez, F. J., de Andrade, J. A., Anstrom, K. J., King, T. E., Jr., & Raghu, G. (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2093–2101. https://doi.org/10.1056/NEJMoa1401739.

    Article  CAS  Google Scholar 

  43. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman, D. A., Schwarz, M., Anstrom, K. J., Collard, H. R., Flaherty, K. R., & Hunninghake, G. W. (2010). A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. New England Journal of Medicine, 363(7), 620–628. https://doi.org/10.1056/NEJMoa1002110.

    Article  Google Scholar 

  44. Noth, I., Anstrom, K. J., Calvert, S. B., De Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., Olman, M. A., & Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). (2012). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 186(1), 88–95. https://doi.org/10.1164/rccm.201202-0314OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. O’Brien, E. C., Hellkamp, A. S., Neely, M. L., Swaminathan, A., Bender, S., Snyder, L. D., Culver, D. A., Conoscenti, C. S., Todd, J. L., Palmer, S. M., Leonard, T. B., & IPF-PRO Registry investigators. (2020). Disease severity and quality of life in patients with idiopathic pulmonary fibrosis: A cross-sectional analysis of the IPF-PRO registry. Chest. https://doi.org/10.1016/j.chest.2019.11.042.

    Article  PubMed  Google Scholar 

  46. Bloem, A. E. M., Mostard, R. L. M., Stoot, N., Vercoulen, J. H., Peters, J. B., Janssen, D. J. A., Custers, J. W., & Spruit, M. A. (2020). Severe fatigue is highly prevalent in patients with IPF or sarcoidosis. Journal of Clinical Medicine, 9(4), 20. https://doi.org/10.3390/jcm9041178.

    Article  Google Scholar 

  47. Moor, C., Kimman, M. L., van Manen, M. J. G., Dirksen, C. D., Wijsenbeek, M. S., & Van Jaarsveld, F. X. (2017). Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis. European Respiratory Journal, 50(suppl 61), PA4884. https://doi.org/10.1183/1393003.congress-2017.PA4884.

    Article  Google Scholar 

  48. Wapenaar, M., Patel, A. S., Birring, S. S., et al. (2017). Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 14(2), 140–150.

    Article  Google Scholar 

  49. McCaffrey, N., Kaambwa, B., Currow, D. C., & Ratcliffe, J. (2016). Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health and Quality of Life Outcomes, 14(1), 133. https://doi.org/10.1186/s12955-016-0537-0.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Center for the evaluation of value and risk in health the cost-effectiveness analysis registry. https://www.cearegistry.org. Accessed 5 Oct 2020.

  51. Nafees, B., Lloyd, A. J., Dewilde, S., Rajan, N., & Lorenzo, M. (2017). Health state utilities in non-small cell lung cancer: An international study. Asia-Pacific Journal of Clinical Oncology, 13(5), e195–e203. https://doi.org/10.1111/ajco.12477.

    Article  PubMed  Google Scholar 

  52. McClure, N. S., Sayah, F. A., Xie, F., Luo, N., & Johnson, J. A. (2017). Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value in Health, 20(4), 644–650. https://doi.org/10.1016/j.jval.2016.11.015.

    Article  PubMed  Google Scholar 

  53. Payakachat, N., Ali, M. M., & Tilford, J. M. (2015). Can the EQ-5D detect meaningful change? A systematic review. Pharmacoeconomics, 33(11), 1137–1154. https://doi.org/10.1007/s40273-015-0295-6.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hyldgaard, C., Hilberg, O., & Bendstrup, E. (2014). How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respiratory Medicine, 108(4), 647–653. https://doi.org/10.1016/j.rmed.2014.01.008.

    Article  PubMed  Google Scholar 

  55. Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015). Mechanisms of human autoimmunity. The Journal of Clinical Investigation, 125(6), 2228–2233. https://doi.org/10.1172/JCI78088.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018). The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Frontiers in Medicine (Lausanne), 5, 43–43. https://doi.org/10.3389/fmed.2018.00043.

    Article  Google Scholar 

  57. Hoyne, G. F., Elliott, H., Mutsaers, S. E., & Prele, C. M. (2017). Idiopathic pulmonary fibrosis and a role for autoimmunity. Immunology & Cell Biology, 95(7), 577–583. https://doi.org/10.1038/icb.2017.22.

    Article  CAS  Google Scholar 

  58. Caffarelli, C., Gonnelli, S., Tomai Pitinca, M. D., Francolini, V., Fui, A., Bargagli, E., Refini, R. M., Bennett, D., Nuti, R., & Rottoli, P. (2016). Idiopathic pulmonary fibrosis a rare disease with severe bone fragility. Internal and Emergency Medicine, 11(8), 1087–1094. https://doi.org/10.1007/s11739-016-1501-z.

    Article  PubMed  Google Scholar 

  59. Ikezoe, K., Handa, T., Tanizawa, K., Kubo, T., Oguma, T., Hamada, S., Watanabe, K., Aihara, K., Sokai, A., Nakatsuka, Y., & Muro, S. (2015). Bone mineral density in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 109(9), 1181–1187. https://doi.org/10.1016/j.rmed.2015.06.014.

    Article  PubMed  Google Scholar 

  60. Peasgood, T., Herrmann, K., & Kanis, J. A. (2009). An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporosis International, 20, 853–868. https://doi.org/10.1007/s00198-009-0844-y.

    Article  CAS  PubMed  Google Scholar 

  61. Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., & Esser, D. (2012). Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. European Respiratory Reviews, 21(126), 355–361. https://doi.org/10.1183/09059180.00002512.

    Article  Google Scholar 

  62. Australian Bureau of Statistics (2020). Australian demographic statistics, December 2019. https://www.abs.gov.au/Population. Accessed 21 July 2020.

  63. Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22. https://doi.org/10.1002/hec.3564.

    Article  PubMed  Google Scholar 

  64. Kim, H. J., Perlman, D., & Tomic, R. (2015). Natural history of idiopathic pulmonary fibrosis. Respiratory Medicine, 109(6), 661–670. https://doi.org/10.1016/j.rmed.2015.02.002.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge staff of the Australian IPF Registry and the Registry Coordinators around Australia for assistance with the recruitment of participants during the study period.

Funding

This study is part of the QUality of LIfE and Costs AssociaTed with Idiopathic Pulmonary Fibrosis Study (QUIET-IPF) a project funded through the NHMRC Centre of Research Excellence in Pulmonary Fibrosis (GNT1116371), and by Foundation partner Boehringer Ingelheim and Program Partners Roche and Galapagos.

Author information

Author notes

  1. E. Haydn Walters and Andrew J. Palmer are joint senior authors.

Authors and Affiliations

  1. Menzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia

    Ingrid A. Cox, Barbara de Graaff, Hasnat Ahmed, Julie Campbell, Petr Otahal, E. Haydn Walters & Andrew J. Palmer

  2. NHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia

    Ingrid A. Cox, Barbara de Graaff, Tamera J. Corte, Ian Glaspole, Nicole Goh, E. Haydn Walters & Andrew J. Palmer

  3. Central Clinical School, The University of Sydney, Camperdown, Australia

    Tamera J. Corte

  4. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia

    Tamera J. Corte

  5. Alfred Hospital, Melbourne, Australia

    Ian Glaspole & Nicole Goh

  6. Monash University, Melbourne, Australia

    Ian Glaspole

  7. Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia

    Yuben Moodley

  8. Institute of Respiratory Health, The University of Western Australia, Perth, Australia

    Yuben Moodley

  9. Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Australia

    Yuben Moodley

  10. Australian Idiopathic Pulmonary Fibrosis Registry, Lung Foundation of Australia, Camperdown, Australia

    Sacha Macansh

  11. Centre for Health Policy, School of Population and Global Health, The University of Melbourne, Melbourne, Australia

    Andrew J. Palmer

Authors
  1. Ingrid A. Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara de Graaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hasnat Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julie Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Petr Otahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamera J. Corte
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ian Glaspole
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuben Moodley
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nicole Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sacha Macansh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. Haydn Walters
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Andrew J. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IAC designed the study, performed statistical analyses, interpreted the results, and wrote the first draft of the manuscript. BdG, EHW, HA and JC contributed to the study design and contributed to the manuscript writing. PO reviewed the statistical analysis and contributed to the manuscript writing. TJC, IG, NG, YM and SM contributed to manuscript writing. AP contributed to conceptualization, study design, review of analyses and manuscript writing. All authors approved of the final version of the manuscript.

Corresponding author

Correspondence to Andrew J. Palmer.

Ethics declarations

Conflicts of interest

TC reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from BMS, personal fees from Promedior, personal fees from Ad Alta, grants from Avalyn Pharma, grants from Biogen, outside the submitted work. IG reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, personal fees from Adalta, personal fees from Accendatech, personal fees from Avalyn Pharma, outside the submitted work; NG reports personal fees from Boehringer-Ingelheim, personal fees from Roche, personal fees from Astra Zeneca, non-financial support from Air Liquide, grants from Lung Foundation Australia, outside the submitted work. All other authors declare that they have no financial/competing interests.

Ethical approval

All study procedures were approved by the University of Tasmania Human Research Ethics Committee (H0016914), Sydney Local Health District, Royal Prince Alfred Zone (Protocol Number X18-0192, Project Number HREC/18/RPAH/269 and SSA/18/RPAH/435), Alfred Health (Site Authorisation Letter 45217) and the Hunter New England Local Health District (SSA/19/HNE/23).

Consent to participate

The authors affirm that signed informed consent was obtained from all individual participants included in this study.

Consent for publication

The authors affirm that individual participants provided informed consent for publication of their data.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 139 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cox, I.A., de Graaff, B., Ahmed, H. et al. The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia. Qual Life Res 30, 2615–2632 (2021). https://doi.org/10.1007/s11136-021-02879-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-021-02879-1

Keywords

Search

Navigation